# Recurrent UTI in Adult Women: Contemporary Management & Future Prospects

Mr Chris Harding Newcastle-upon-Tyne Hospitals UK Chairman British Association of Urological Surgeons FNUU Section TWITTER: @chrisharding123

#### Disclosures

#### Speaker

- Astellas
  Pfizer
- Allergan
- Medtronic
- BBraun
- Advisory Boards / Consultancy
- Pierre Fabre
- AMS
- Astellas
- Teleflex

## **Urinary Tract Infection**


- Defined as the inflammatory response of the urothelium to microbial pathogens
- Affect an estimated 150 million people each year worldwide stamm & Norrby 2001 J. Infect. Dis. 183, S1–S4
- UTIs account for 17.2% of all nosocomial infections in England Loveday et al. J. Hosp. Infect. 86, S1–S70 (2014).
- Recurrence accounted for 10.5 million outpatient consultations and 2–3 million emergency department visits in the USA alone Nicolle Crit. Care Clin.29, 699–715 (2013).


# Definition of recurrent UTI?


- No universally accepted definition for rUTI
- Most commonly used is "2 in 6 months or 3 in a year"
   Schoof and Hill 2005 Hooton and Stamm 2006
- Estimated 20-50% of young women with UTI will have another within a year

Mabeck *et al* Postgrad Med J 1972. Brumbaugh and Mobley Expert Rev Vaccines. 2012.

 Finnish study showed older (>55yrs) more likely to have recurrence in first year (53% vs 36%) Ikaheimo Clin Infect Dis 1996










Contemporary Management

## **Contemporary Management**

- Non-antibiotic (and non-invasive)
  - Cranberry Products
  - Topical Oestrogens
  - Methenamine Hippurate
  - Vaccines
- Antibiotics
  - Prophylactic Antibiotics
  - Self Start Therapy
- Intravesical agents



# **Cranberry Products**

- Postulated to acidify urine and reduce bacterial adhesion/prevent fimbrial expression
- Some evidence that rUTIs reduced but optimum dose /duration unclear.
- Original Cochrane review (2008) identified some benefit
   BUT

Meta-analyses in updated review (2012) showed that compared with placebo, water or non-treatment,

 "cranberry products did not significantly reduce the occurrence of symptomatic UTI overall"
 (RR 0.86, 95% Cl 0.71 to 1.04) Jepson et al. Cochrane Database 2012

2

#### **Cranberry Products**

ASN

Consumption of a cranberry juice beverage lowered the number of clinical urinary tract infection episodes in women with a recent history of urinary tract infection<sup>1</sup> *knic (Mali<sup>1,16</sup> Kerric I, Kappa<sup>2</sup> Continue Klow<sup>2</sup> Linka II Derrig<sup>2</sup> Aniume L Solidi<sup>2</sup> and Kalpaus Gapa<sup>3,6</sup>* 

Biofortis Clinical Research, Addison, IL: <sup>2</sup>MB Clinical Research, Glea Ellyn, IL: <sup>4</sup>Ocean Spray Crasherries, Lakeville-Middleboro, MA: <sup>8</sup>Departm Indicine, Bowen University School of Medicine, Bosters, MA: and <sup>4</sup>VA Bostern Healthcare System, Bosten, MA

- Study funded by Ocean Spray Cranberries 2 authors by the company published Am J Clin Nutr; 2016 Jun; 103:1434-42
- 6/52 trial in 373 healthy women randomised to a 240ml bottle of cranberry juice or identical-tasting placebo daily
- 39 investigator-diagnosed episodes of clinical UTI in the cranberry group compared with 67 episodes in the placebo group (antibiotic use–adjusted incidence rate ratio: 0.61; P = 0.016)
- For every woman who drank cranberry juice for 3.2 years, just one UTI would be prevented

## **Topical Oestrogens**

- Falling oestrogen levels lead to a change in vaginal flora and pH
- Local oestrogen can reverse this without SE of systemic oestrogen
   Esposito *et al.* Gynaecological Endocrinology 1991
- Oestrogen may also enhance innate immune mechanisms against urinary tract infection

Lüthje et al. Science Translational Medicine 2013

Perrotta et al. Cochrane Database 2008


 Systematic review found no reduction in UTIs with oral oestrogen but showed vaginal preparations superior to placebo (RR 0.25/0.64)

# Varianti costrol Varianti costrol Raz. 1983 8.50 27.43 3 Eriksen 1989 27.53 44.65 2 Dr L. Subbrail (+equared - 85.3%, p = 0.009) 0.42 (0.47, 0.86) 0.42 (0.36, 100) M-H Subtrail 0.42 (0.37, 0.86) 0.42 (0.37, 0.86)

# Methenamine Hippurate

- Methenamine has antibacterial properties hydrolysed to formaldehyde in acid urine
- Systematic review highlighted heterogeneity of data but some studies report reduction in symptomatic UTIs (RR 0.24)
- ? Ineffective in pts with neuropathic bladder / abnormal renal tract.
- "There is a need for further large well-conducted RCTs to clarify..."


Study or subgroup	Treatment n/N	Control n/N	Risk Ratio N - H, Randon, 95N CI	Weight	Risk Ratio N - H, Random, 95% Cl	
Furness 1975	14/70	17/67	-	25.6 %	0.79 [ 0.42, 1.47 ]	
Knoff 1985	1/31	\$/29		10.2 %	0.12[0.02, 0.88]	
Lee 2007	67/150	71/155		29.6 %	0.98 [ 0.76, 1.25 ]	
Pettersson 1989	5/47	1/45		9.6%	4.79 [ 0.58, 39.40 ]	
Schiotz 2002	2/75	10/75		14.7 %	0.20 [ 0.05, 0.88 ]	
Tyreman 1986	1/51	14/58 -		10.3 %	0.08 [ 0.01, 0.60 ]	
Total (95% CI) Total events: 30 (Treatmen Heterogeneity: Tau <sup>2</sup> = 0.33 Test for overall effect: 2 = Test for subgroup differen	3; Chi <sup>2</sup> = 18.15, df = 5 1.57 (P = 0.12)	429 Ø = 0.0031; I <sup>a</sup> =725	*	100.0 %	0.53 [ 0.24, 1.17 ]	
			1 1 10			
	,	0.0 avours treatment	01 0.1 1 10 Favours co	100 ntrol		



Primary Outcome – UTI incidence

## Vaccines

- Uro Vaxom<sup>®</sup> (OM-89) is only one recommended by EAU guidelines EAU Guidelines Urological Infections 2018
- Oral administration of immunologically active bacterial lysates of 18 *E coli* strains . Better than placebo in several RCTs.
- The vaginal vaccine Urovac<sup>®</sup> slightly reduced UTI recurrence and increased time to re-infection.
- New agent, UROMUNE<sup>®</sup> (under the tongue spray) currently undergoing multi-centre trials in Spain with UK trial planned.



# **Prophylactic Antibiotics**

- Long term prophylaxis can range from 4 mths to 5 yrs!!
  95% will remain UTI free but 50% relapse following
- cessation Nicolle et al. Am J Med 2002
- Cochrane review of RCT's **RR 0.21** for single recurrence (NNT 1.85) but RR after prophylaxis 0.82 Albert *et al.* Cochrane Database 2004
- Single randomised study found prophylactic nitrofurantoin superior to oestrogen


Raz et al. Clin Infect Dis 2003

#### Antibiotic prophylaxis

Study or subgroup	Antibiotic n/N	Placebo n/N	Risk Ratio M-H, Random, 95% CI	Weight	Risk Ratio M - H, Random, 95% Cl
Microbiologio	al UTI duri	ng prophyla	(IS		
Total (95% CI) Total events: 24 (Antibior Heterogeneity: Tau <sup>2</sup> = 0. Test for overall effect: 2 =		<b>177</b> 10 (P = 0.18); P =28%	•	100.0 %	0.21 [ 0.13, 0.34 ]
		0.005 Favours Antibiotic	0.1 1 10 Favours Pl	200 acebo	NNToT = 1.85
Microbiologio	al UTI afte	r completion	of prophylaxis		
Total (95% CI) Total events: 23 (Antibio Heterogeneity: Tau <sup>4</sup> = 0. Test for overall effect: 2 -		26 2 (P = 0.11); P =54N		100.0 %	0.82 [ 0.44, 1.53 ]
		0.2 Favours Antibiotic	0.5 1 2 Favours Pl	5	
			Albert et a	. Cochrane Data	base Syst Rev. 2004;(3):CD0012

# Self Start Antibiotics

- 85-95% of women with previous UTI can self diagnose successfully Gupta *et al.* Ann Intern Med 2001
- Clinical and Microbiological cure rates > 90%
- Best used in motivated women with previous culture confirmed cystitis
   Hooton NEJM 2012
- Advantages are less antimicrobial exposure and high patient satisfaction rates
- Post coital antibiotics reserved for group where it has been identified as the dominant risk factor.



# REVIEWS

Nonantibiotic prevention and management of recurrent urinary tract infection Neha Shira', Anna Coodmai', Anana Zakri', Arun Sahai' and Sachin Malde' \*


- Systematic review of all grades of evidence Nature Reviews. Urology 2018, 15 (12): 750-776
- Thorough, detailed analysis of existing literature

Future Prospects

# **Future Prospects**

- New antibiotics
- Vaccination
  - Mucosal multivalent bacterial vaccine
- Virulence factor vaccines
- Bacterial Adhesion Inhibitors
- Immune Modulation
  - Boosting bacterial expulsion
- Exogenous enhancement of innate immunityNatural flora modulation

  - ProbioticsGastrointestinal decolonisation
- Acupuncture





# **New Antibiotics**

- Ceftolozane/tazobactam
  - novel cephalosporin combined with an established BLI
  - phase 3 study a total of 1083 hospitalized patients with complicated UTI or acute pyelonephritis
  - randomized 1:1 to ceftolozane/tazobactam (1.5 g IV tds) or levofloxacin (750 mg IV od) for 7 d.
  - Overall, ceftolozane/tazobactam showed better responses than levofloxacin

Wagenlehner et al Lancet 2015;385:1949–56


# **New Antibiotics**


#### • Ceftazidime/avibactam


- Avibactam, a BLI, restores the activity of ceftazidime against several bacteria (eg, ESBL)
- 2 phase 3 trials 1033 patients with cUTI/APN randomized to ceftazidime/avibactam (2000/500 mg IV tds) or doripenem (500 mg IV tds)
- Noninferiority was demonstrated for symptomatic resolution
- Microbiological eradication was superior for ceftazidime/avibactam

Wagenlehner FM at alClin Infect Dis 2016;63:754-62.

# Importance of Innate Immunity










Table 1. Comparative anatomic dissemination of the mucosal SIgA antibody response after           different routes of immunization				
	Sublingual	Nasal	Oral	
Upper respiratory	+++	+++	-	
Lower respiratory	+++	+ to +++	-	
Stomach	+/+++	-	+/+++	
Small intestine	+++		+++	
Colon	?	-	±	
Rectum	?	-	±	
Genital tract	+++	++	-	
Blood	++	+++	+	
Sublingual				

# Uromune<sup>®</sup> Multivalent Bacterial vaccine

A suspension of selected strains of 10<sup>9</sup> inactivated bacteria/mL, for mucosal oral/sublingual administration (spray).

- Escherichia coli
- Klebsiella pneumoniae
- Proteus vulgaris
- Enterococcus faecalis



#### Int Urogynecol J (2013) 24:127–134 DOI 10.1007/s00192-012-1853-5

ORIGINAL ARTICLE

#### Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics

M. F. Lorenzo-Gómez • B. Padilla-Fernández • F. J. García-Criado • J. A. Mirón-Canelo • A. Gil-Vicente • A. Nieto-Huertos • J. M. Silva-Abuin

Received: 11 April 2012 /Accepted: 3 June 2012 /Published online: 18 July 2012 © The Author(s) 2012. This article is published with open access at Springerlink.com

# Uromune<sup>®</sup> - 15month Trial

- Observational retrospective study
- 319 patients with prophylactic treatment:
- Uromune: 159 patients treated during 3 months (group A)
- SMX/TMP: 160 patients treated during 6 months (group B)
- Evaluation variables:
  - Number of UTIs before the treatment.
  - Number of episodes of UTI after the initiation of treatment.
     Number of positives urocultures (UC+).
- Data collection:
- Before the treatment's beginning.
- After 3, 9 and 15 months of treatment's initiation.

#### Uromune<sup>®</sup> - Patients' Epidemiological Data (before treatment)


	A (Uromune)	B (SMX/TMP)	Р
Age (years)	47.7	48.1	0.8536
Range of age	16-85	16-87	
Months of evolution	56.7	59.2	0.7641
Average of UTI in 6M	3.2	3.1	0.2789
Average of UC+ in 6M	2.4	2.2	0.6392
Average of UTI/month	0.53	0.51	0.6408
Average of UC+/month	0.41	0.36	0.2788

# Uromune<sup>®</sup> - Trial Results

• Average number of episodes of UTI/month.

	Uromune	SMX/TMP	Р
Pre	0.53	0.51	0.6408
0 to 3M	0.12	0.53	< 0.0001
0 to 9M	0.08	0.41	< 0.0001
0 to 15M	0.09	0.38	< 0.0001
3 to 9M	0.06	0.35	< 0.0001
3 to 15M	0.08	0.35	< 0.0001
9 to 15M	0.10	0.34	< 0.0001

#### Vaccination Against Virulence Factors



# Fimbriae


- Fimbriae or Pili are Filamentous organelles expressed on the surface of gram-negative bacteria and mediate attachment to host tissues.
- First described by Duguid et al. in 1955
- Found on a variety of gram-negative bacteria including saprophytes, commensals and pathogens.
- Adhesin (FimH) binds to mannose oligosacchaarides attached to uroplakin on surface of urinary bladder epithelium



CFU/kidney

10<sup>5</sup>





Solomon Langermann et al. Science 276:607-611


 Fimbrial adhesin FimH has been used as an effective vaccine antigen in mouse models.

Kidney

Infection

- Less immmunogenicity and lack of safe & effective adjuvant has prevented use in humans.
- Several new safe and efficacious adjuvants for human use, which will faciitate use of FimH vaccines in clinical trials.

# **Bacterial Adhesion Inhibitors**




Spaulding and Hultgren Pathogens 2016; 5(1), 30.

- FimH-mediated cellular adhesion to mannosylated proteins is critical for uropathogenic E. coli (UPEC) to invade bladder epithelium.
- Small-molecule FimH bacterial adhesion antagonists, mannosides, have been developed and awaiting trials.

## **Bacterial Adhesion Inhibitors**

- D-mannose postulated to prevent UPEC binding to urothelium via competative antagonism
- Single RCT involving 308 women randomised to

   NFT
  - D mannose
  - No Prophylaxis
- RR 0.24 p <0.0001




#### Immune Modulation: Exogenous Enhancement of Innate Immunity

- Innate immunity provides the immediate defences against infection and is the most important part of the body's response to UTI.
- Over the past 5-years, greater realisation that Estrogen enhances innate immunity. In particular, Estrogen enhances secretion of antimicrobial peptides (AMPs) in bladder and vaginal cells
- Antimicrobial peptides are:
  - Gene encoded 'natural antibiotics' secreted at epithelial surfaces.
  - Small, +ve charged (cationic) molecules
     Broad spectrum (kill gram +ve & -ve
  - bacteria, fungi & some viruses)> Target & disrupt microbial membranes
  - Target & disrupt microbial membra



#### **Exogenous Enhancement of Innate Immunity**



# Probiotics

- Probiotic therapy and faecal transplant used successfully in treating severe *C.dificile* and pseudomembranous colitis.
- UTIs often preceded by presence of pathogenic microbiota in the vagina and urethra.
- Possible prevention strategy could be to normalise vaginal and urethral microflora by direct administration of probiotics
- Possibilities:
  - Innoculate asymtomatic bacteruria (ABU) strains of *E. coli* into bladder
  - Use commensal Lactobacilli in vagina to 'out-colonise' E. coli
  - Oral probiotics to displace pathogenic E. coli in gut

# Probiotics

- Randomised study vs placebo of 100 women with a history of recurrent UTI
- UTI occurred in 7/48 15% of women receiving Lactin-V vs 13/48 27% of women receiving placebo (relative risk [RR], 0.5)
- High-level vaginal colonisation with Lactobacillus was associated with significant reduction in rUTI
- Authors concluded that "Lactin-V after treatment for cystitis is associated with a reduction in recurrent UTI."
- EAU guidelines suggest that Lactobacillus may be used in rUTI where suitable preparations available

# **Gastrointestinal Decolonisation**

- Transplant pyelonephritis caused by ESBL *E. coli* intestinal colonization is a problem in renal transplant patients.
  - Decline in renal function with rUTI can result in ESRF necessitating further transplantation
  - But can't transplant while still colonised.
- Recently, first case report published of a patient with recurrent episodes of transplant pyelonephritis decolonized for ESBL-producing *E. coli* with a faecal microbiota transplantation.
  - Two weeks after faecal transplantation the rectal culture became ESBL negative.
  - During the follow up the patient did not develop symptoms of a UTI.

Singh R et al. Clin. Microbiol. Infect. 2014, 20, 977–978

## Conclusions

- rUTI is prevalent in adult women.
- Non-antibiotic treatments preferable for recurrent UTI *where possible...*
- Several treatment options exist for rUTI with varying levels of supporting evidence.
- Further RCTs are needed to evaluate these treatments.
- New non-antibiotics treatments on the horizon

# Acknowledgements

- Ased Ali, Pinderfields Hospital, UK
- Rob Pickard, Newcastle University, UK
- Judith Hall, Newcastle University, UK
- Khalil Ahmed, Syner-Med , UK
- Soman Abraham, Duke University, NC, USA
- Scott Hultgren, Washington University School of Medicine, MO, USA